Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Rachel Elizabeth Raab"'
Autor:
Oludamilola Olajide, David A. Flockhart, Daniel L. Hertz, William J. Irvin, Steven M. Anderson, Karen E. Weck, Steven W. Corso, Jeffrey Peppercorn, David R. Jones, Zeruesenay Desta, Gustav Magrinat, Joseph G. Ibrahim, Anna C. Snavely, Daniel R. Carrizosa, Christine M. Walko, Susan E. Moore, Rachel Elizabeth Raab, Lisa A. Carey, James P. Evans, Howard L. McLeod, Garry Schwartz
Publikováno v:
British Journal of Clinical Pharmacology. 80:1122-1130
Aims A prospectively enrolled patient cohort was used to assess whether the prediction of CYP2D6 phenotype activity from genotype data could be improved by reclassification of diplotypes or alleles. Methods Three hundred and fifty-five patients recei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06094b83820dbacca61d5d9591033ea6
https://doi.org/10.1111/bcp.12665
https://doi.org/10.1111/bcp.12665
Autor:
Karen E. Weck, Christine M. Walko, Steven W. Corso, Susan E. Moore, Rachel Elizabeth Raab, Gary Schwartz, James P. Evans, Joseph G. Ibrahim, Jeffrey Peppercorn, Peter Rubin, Oludamilola Olajide, David A. Flockhart, Howard L. McLeod, Daniel L. Hertz, Zeruesenay Desta, William J. Irvin, Lisa A. Carey, Steven M. Anderson, Daniel R. Carrizosa, Anna C. Snavely
Publikováno v:
Cancer Research. 75:P1-03
Background: Tamoxifen is a selective estrogen receptor modulator that is the most commonly used and cost effective hormonal agent for pre-menopausal hormone-receptor positive breast cancer patients. CYP2D6 activity phenotype, which is classified by g
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7eda72b1941d239b23f56e7a33844caa
https://doi.org/10.1158/1538-7445.sabcs14-p1-03-02
https://doi.org/10.1158/1538-7445.sabcs14-p1-03-02
Autor:
Mark Graham, Daniel L. Hertz, William J. Irvin, Joseph G. Ibrahim, Oludamilola Olajide, Karen E. Weck, James P. Evans, Allison M. Deal, Jeffrey Peppercorn, Christine M. Walko, Steven M. Anderson, Lisa A. Carey, David R. Jones, Susan E. Moore, Rachel Elizabeth Raab, Steven W. Corso, Zeruesenay Desta, Gustav Magrinat, David A. Flockhart, Daniel R. Carrizosa, Howard L. McLeod, Garry Schwartz
BACKGROUND Polymorphic CYP2D6 is primarily responsible for metabolic activation of tamoxifen to endoxifen. We previously reported that by increasing the daily tamoxifen dose to 40 mg/day in CYP2D6 intermediate metabolizer (IM), but not poor metaboliz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a10a5ebac4286ceaa1a874712d85930
Publikováno v:
Annals of Surgical Oncology. 19:3251-3256
Patient navigation programs are initiated to help guide patients through barriers in a complex cancer care system. We sought to analyze the impact of our patient navigator program on the adherence to specific Breast Cancer Care Quality Indicators (BC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04e70b963a1acc506a6a75a1c32e2231
https://doi.org/10.1245/s10434-012-2527-8
https://doi.org/10.1245/s10434-012-2527-8
Autor:
Rachel Elizabeth Raab, Maxwell P. Lee, Galina Khramtsova, Tara J. Taylor, Kent W. Hunter, C. Ryan Miller, Songjoon Baek, Fan Cheng, Howard H. Yang, Olufunmilayo I. Olopade, Jung S. Byun, Kevin Gardner, Madeline M. Wong, Cecilia Zvosec, Charles M. Perou, Lijun Di, Sven Bilke, Clay Wakano
Publikováno v:
Nature communications
The C-terminal binding protein (CtBP) is a NADH-dependent transcriptional repressor that links carbohydrate metabolism to epigenetic regulation by recruiting diverse histone-modifying complexes to chromatin. Here global profiling of CtBP in breast ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63944f9d4ff8bcc9fee01ea71fca2b2a
Publikováno v:
Journal of Clinical Oncology. 34:e12502-e12502
e12502Background: TNBC lacks effective targeted therapies, limiting treatment to cytotoxic chemotherapy alone. One third of patients with TNBC achieve pathologic complete response (pCR) with standard neoadjuvant chemotherapy (Cortazar Lancet 2014). C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c6538abdf2016d7bac7f5f3b4dd90307
https://doi.org/10.1200/jco.2016.34.15_suppl.e12502
https://doi.org/10.1200/jco.2016.34.15_suppl.e12502
Autor:
Mark L. Graham, William J. Irvin, Oludamilola Olajide, Karen E. Weck, Christine M. Walko, Sean Thomas Canale, Steven W. Corso, E. Claire Dees, Susan G. Moore, Rachel Elizabeth Raab, Lisa A. Carey, Wing Keung Chiu, Evan T. Ogburn, Howard L. McLeod, Steven M. Anderson, David A. Flockhart, James P. Evans, Joseph G. Ibrahim, Zeruesenay Desta, Kenneth J. Friedman, Jeffrey Peppercorn
Purpose We examined the feasibility of using CYP2D6 genotyping to determine optimal tamoxifen dose and investigated whether the key active tamoxifen metabolite, endoxifen, could be increased by genotype-guided tamoxifen dosing in patients with interm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7789f91bc41a7021c146258ba182078
https://europepmc.org/articles/PMC3158597/
https://europepmc.org/articles/PMC3158597/
Autor:
Rachel Elizabeth Raab, Lawrence B. Marks, Sarah E. James, Lisa A. Carey, Timothy M. Zagar, Tithi Biswas, Paul R. Walker, Jimmy T. Efird, Shreya Prasad
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 87:S99-S100
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91404c8bfb9aaf44743dfcbaca4d707c
https://doi.org/10.1016/j.ijrobp.2013.06.257
https://doi.org/10.1016/j.ijrobp.2013.06.257
Autor:
Paul R. Walker, Jimmy T. Efird, Timothy M. Zagar, Shreya Prasad, Rachel Elizabeth Raab, Sarah E. James, Tithi Biswas
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 87:S98-S99
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7675e69858bb43cf3fa0f2a70029047
https://doi.org/10.1016/j.ijrobp.2013.06.255
https://doi.org/10.1016/j.ijrobp.2013.06.255
Autor:
Sean Thomas Canale, Daniel R. Carrizosa, Anna C. Snavely, Lisa A. Carey, Rachel Elizabeth Raab, Daniel L. Hertz, Mark L. Graham, William J. Irvin, Steven M. Anderson, Howard L. McLeod, Susan G. Moore, Oludamilola Olajide, Peter Rubin, James P. Evans, Joseph G. Ibrahim, Karen E. Weck, Steven W. Corso, Garry Schwartz, Kenneth J. Friedman, Jeffrey Peppercorn
Publikováno v:
Journal of Clinical Oncology. 32:561-561
561 Background: Tamoxifen treated breast cancer patients with diminished CYP2D6 activity have lower endoxifen exposure, which may lead to inferior treatment outcomes. Increasing the daily tamoxifen...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::749db53894c1555bd59b62257dfd9405
https://doi.org/10.1200/jco.2014.32.15_suppl.561
https://doi.org/10.1200/jco.2014.32.15_suppl.561